Form 8-K - Current report:
SEC Accession No. 0001558370-24-012783
Filing Date
2024-09-13
Accepted
2024-09-13 17:15:19
Documents
15
Period of Report
2024-09-13
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K chrs-20240913x8k.htm   iXBRL 8-K 45855
  Complete submission text file 0001558370-24-012783.txt   204496

Data Files

Seq Description Document Type Size
2 EX-101.SCH chrs-20240913.xsd EX-101.SCH 4528
3 EX-101.DEF chrs-20240913_def.xml EX-101.DEF 3158
4 EX-101.LAB chrs-20240913_lab.xml EX-101.LAB 12264
5 EX-101.PRE chrs-20240913_pre.xml EX-101.PRE 11151
17 EXTRACTED XBRL INSTANCE DOCUMENT chrs-20240913x8k_htm.xml XML 4903
Mailing Address C/O DENNIS M. LANFEAR 333 TWIN DOLPHIN DR, SUITE 600 REDWOOD CITY CA 94065
Business Address C/O DENNIS M. LANFEAR 333 TWIN DOLPHIN DR, SUITE 600 REDWOOD CITY CA 94065 (650) 649-3530
Coherus BioSciences, Inc. (Filer) CIK: 0001512762 (see all company filings)

EIN.: 273615821 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36721 | Film No.: 241298602
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)